RS51467B - Prolekovi za ligande nmda receptora - Google Patents

Prolekovi za ligande nmda receptora

Info

Publication number
RS51467B
RS51467B YUP-130/03A YUP13003A RS51467B RS 51467 B RS51467 B RS 51467B YU P13003 A YUP13003 A YU P13003A RS 51467 B RS51467 B RS 51467B
Authority
RS
Serbia
Prior art keywords
formula
compound
piperidin
benzyl
hydroxy
Prior art date
Application number
YUP-130/03A
Other languages
English (en)
Serbian (sr)
Inventor
Alexander Alanine
Emmanuel Pinard
Bernd Buettelmann
Holger Fisher
Marie-Paule Heitz Neidhart
Joerg Huwyler
Georg Jaeschke
René Wyler
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of YU13003A publication Critical patent/YU13003A/sh
Publication of RS51467B publication Critical patent/RS51467B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
YUP-130/03A 2000-08-21 2001-08-20 Prolekovi za ligande nmda receptora RS51467B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
PCT/EP2001/009561 WO2002016321A1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (2)

Publication Number Publication Date
YU13003A YU13003A (sh) 2006-05-25
RS51467B true RS51467B (sr) 2011-04-30

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-130/03A RS51467B (sr) 2000-08-21 2001-08-20 Prolekovi za ligande nmda receptora

Country Status (35)

Country Link
US (1) US6407235B1 (enExample)
EP (1) EP1313703B1 (enExample)
JP (1) JP4162991B2 (enExample)
KR (1) KR100589991B1 (enExample)
CN (1) CN1227230C (enExample)
AR (1) AR030373A1 (enExample)
AT (1) ATE386022T1 (enExample)
AU (2) AU2001285894B2 (enExample)
BR (1) BR0113348A (enExample)
CA (1) CA2419279C (enExample)
CY (1) CY1107937T1 (enExample)
CZ (1) CZ303319B6 (enExample)
DE (1) DE60132782T2 (enExample)
DK (1) DK1313703T3 (enExample)
EC (1) ECSP034489A (enExample)
EG (1) EG24293A (enExample)
ES (1) ES2299508T3 (enExample)
HR (1) HRP20030125B1 (enExample)
HU (1) HU229802B1 (enExample)
IL (1) IL154254A0 (enExample)
JO (1) JO2289B1 (enExample)
MA (1) MA26947A1 (enExample)
MX (1) MXPA03001311A (enExample)
MY (1) MY136065A (enExample)
NO (1) NO324941B1 (enExample)
NZ (1) NZ523990A (enExample)
PA (1) PA8525601A1 (enExample)
PE (1) PE20020291A1 (enExample)
PL (1) PL204215B1 (enExample)
PT (1) PT1313703E (enExample)
RS (1) RS51467B (enExample)
RU (1) RU2272027C2 (enExample)
SI (1) SI1313703T1 (enExample)
WO (1) WO2002016321A1 (enExample)
ZA (1) ZA200300894B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300235A2 (hu) * 2000-03-21 2003-08-28 The Procter & Gamble Co. Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US8759400B2 (en) * 2005-12-19 2014-06-24 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
CN105683180B (zh) 2013-11-05 2020-01-21 阿斯利康(瑞典)有限公司 Nmda拮抗剂前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420053T2 (de) * 1994-01-31 1999-11-25 Pfizer Inc., New York Neuroprotektive chroman verbindungen
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
ZA200300894B (en) 2004-04-30
BR0113348A (pt) 2003-07-08
JP2004506715A (ja) 2004-03-04
PL204215B1 (pl) 2009-12-31
ECSP034489A (es) 2003-03-31
EG24293A (en) 2009-01-08
HRP20030125A2 (en) 2005-02-28
IL154254A0 (en) 2003-09-17
MY136065A (en) 2008-08-29
CZ2003492A3 (cs) 2004-01-14
EP1313703A1 (en) 2003-05-28
JP4162991B2 (ja) 2008-10-08
ES2299508T3 (es) 2008-06-01
CA2419279C (en) 2008-10-14
DK1313703T3 (da) 2008-05-19
DE60132782D1 (de) 2008-03-27
HUP0301548A2 (hu) 2003-08-28
AR030373A1 (es) 2003-08-20
DE60132782T2 (de) 2009-02-05
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
CZ303319B6 (cs) 2012-08-01
KR100589991B1 (ko) 2006-06-15
NZ523990A (en) 2004-09-24
KR20030022417A (ko) 2003-03-15
JO2289B1 (en) 2005-09-12
PA8525601A1 (es) 2002-04-25
AU2001285894B2 (en) 2006-06-15
PE20020291A1 (es) 2002-04-17
CN1447793A (zh) 2003-10-08
CA2419279A1 (en) 2002-02-28
US6407235B1 (en) 2002-06-18
RU2272027C2 (ru) 2006-03-20
EP1313703B1 (en) 2008-02-13
MA26947A1 (fr) 2004-12-20
NO20030781L (no) 2003-02-19
NO20030781D0 (no) 2003-02-19
CY1107937T1 (el) 2013-09-04
ATE386022T1 (de) 2008-03-15
US20020040037A1 (en) 2002-04-04
SI1313703T1 (sl) 2008-06-30
MXPA03001311A (es) 2003-06-30
AU8589401A (en) 2002-03-04
HRP20030125B1 (en) 2011-07-31
WO2002016321A1 (en) 2002-02-28
HUP0301548A3 (en) 2010-03-29
PL361387A1 (en) 2004-10-04
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28

Similar Documents

Publication Publication Date Title
DE69528485T2 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
JP3302351B2 (ja) 神経栄養活性および神経保護活性を有する４−アリール−１−フェニルアルキル−１，２，３，６−テトラヒドロピリジン
US5034402A (en) Methods and pharmaceutical compositions using pyrrolidine derivatives
EP0161422B1 (en) Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient
RS52881B (sr) Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze
RS51467B (sr) Prolekovi za ligande nmda receptora
EP0918767A1 (en) Pharmaceutical for treating of neurological and neuropsychiatric disorders
CN101720316A (zh) 新肽去甲酰基酶抑制剂化合物及其制备方法
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
EP0389425B1 (de) Neue Benzothiopyranylamine
NZ533188A (en) Prodrugs to D-prolines
EP1736474A1 (en) Piperidine derivative
FR2647785A1 (fr) Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant
Yadav et al. Stereoselective Synthesis of (R)‐3‐Methylthalidomide by Piperidin‐2‐one Ring Assembly Approach
WO1995025100A1 (fr) Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes
US5145869A (en) Phenylsulfonylalkanoic acid compounds and pharmaceuticals thereof
EP0211220A1 (de) Pyridazo[1,2-a][1,2]diazepinderivate, Zwischenprodukte und Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
TWI306453B (en) Prodrugs to nmda receptor ligands, process for preparing the same and medicament comprising the same
JPS625984A (ja) ピリダゾ〔１，２−ａ〕〔１，２〕ジアゼピン誘導体
HRP930978A2 (en) Hydroxamic acid derivatives